Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes Featured Article: Claudia Cavelti-Weder, M.D., Andrea Babians-Brunner, M.D.,

Slides:

Advertisements

Similar presentations

Targeting inflammation in the treatment of

Advertisements

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin Featured Article: Beverley Balkau, Philip D. Home, Maya Vincent,

New Insulin Glargine 300 Units∙mL2-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial Featured Article: Ravi Retnakaran, Caroline K.

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

LymphoStat-BTM A Case Study for Endpoints and Trial Design in SLE

An Automated Internet Behavioral Weight-Loss Program by Physician Referral: A Randomized Controlled Trial Featured Article: J. Graham Thomas, Tricia M.

Both Dietary Protein and Fat Increase Postprandial Glucose Excursions in Children With Type 1 Diabetes, and the Effect Is Additive Featured Article: Carmel.

Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.

Danny McAuley Queen’s University of Belfast Scottish Combined Critical Care Conference September 2010 Statins in ARDS.

Journal Club 2009 年 1 月 29 日（木） 8 ： 20 ～ 8 ： 50 B 棟 8 階カンファレンスルーム薬剤部 TTSP 石井英俊.

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.

Design: A randomized, prospective, double-blind cohort followed for 16 weeks RenehaVis Original Study 50 DMW 50 HMW 50 LMW 50 Placebo.

Metabolic Effects of Bariatric Surgery

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,

Effectiveness of Early Intensive Therapy On β-Cell Preservation in Type 1 Diabetes Featured Article: Bruce Buckingham, M.D., Roy W. Beck, M.D., P.H.D.,

Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes Featured Article: Aris Siafarikas, F.R.A.C.P., M.D., Robert J.

Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.

Intake of Lactobacillus reuteri Improves Incretin and Insulin Secretion in Glucose Tolerant Humans: A Proof of Concept Featured Article: Marie-Christine.

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.

Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article:

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.

Multicenter Study of Infliximab for Refractory Uveoretinitis in Behçet Disease Okada AA, Goto H, Ohno S, Mochizuki M; Ocular Behçet’s Disease Research.

Moderate Amounts of Fructose Consumption Impair Insulin Sensitivity in Healthy Young Men: A Randomized Controlled Trial Featured Article: Isabelle Aeberli,

Increased Toll-Like Receptor Activity in Patients With Metabolic Syndrome Featured Article: Ishwarlal Jialal, M.D., Ph.D., Beverley A. Huet, Ph.D., Harmeet.

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population: Receiver Operating Characteristic Analysis Featured.

High Concentrations of AGE-LDL and Oxidized LDL in Circulating Immune Complexes Are Associated With Progression of Retinopathy in Type 1 Diabetes Featured.

Interleukin-1-Receptor Antagonist in Type 2 Diabetes Mellitus Claus M. Larsen, M.D., Mirjam Faulenbach, M.D., Allan Vaag, M.D., Ph.D., Aage Vølund, M.Sc.,

Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomized open-label controlled trial Yves.

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

Gerti Tashko, M.D. DM Journal Club 12/16/2010. The use of exenatide with insulin is not FDA approved. The study was designed to evaluate if exenatide.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

Featured Article: Wayne H.-H. Sheu, Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Arpana Mirza, Barry J. Goldstein, Keith D. Kaufman, and Samuel S. Engel.

A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation Michael Camilleri, M.D., Rene Kerstens, M.Sc., An Rykx, Ph.D., and Lieve Vandeplassche,

GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose- Ranging.

R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.

Farletuzumab in platinum sensitive ovarian cancer with low CA125

8. Causality assessment:

Neal B, et al. Diabetes Care 2015;38:403–411

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

ACC 2018 Orlando, Florida Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes A Pre-Specified Secondary Endpoint from.

ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.

Krop I et al. SABCS 2009;Abstract 5090.

Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled.

Trial profile John A Dormandy et al. Lancet 2005;366:

PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.

Diabetes Journal Club March 17, 2011

Phase 2 Multicenter Study Results of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple.

Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases Dhavalkumar D. Patel, MD, PhD, Christian Antoni,

Volume 24, Issue 5, Pages (May 2016)

ADAb: anti-drug antibody.

The American College of Cardiology Presented by Dr. Timothy Henry

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma1 Phase 3 Randomized Study of Ipilimumab (IPI) plus Dacarbazine (DTIC) vs DTIC.

Pramlintide Therapy Part 1of 2

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Enrollment, outcomes, and pharmacokinetics.

Cytokine changes in LPS-induced TNFα and spontaneous IL-6 production in whole-blood cultures. Cytokine changes in LPS-induced TNFα and spontaneous IL-6.

Björn Bornkamp, Georgina Bermann

ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.

Late-Breaking Data on LDL-C Reduction

Presentation transcript:

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes Featured Article: Claudia Cavelti-Weder, M.D., Andrea Babians-Brunner, M.D., Cornelia Keller, M.D., Marc A. Stahel, M.D., Malaika Kurz-Levin, M.D., Hany Zayed, Ph.D., Alan M. Solinger, M.D., Thomas Mandrup-Poulsen, M.D., Ph.D., Charles A. Dinarello, M.D., Marc Y. Donath, M.D. Diabetes Care Volume 35: August, 2012

Study Objective Metabolic activation of the innate immune system governed by interleukin (IL)-1β contributes to β-cell failure in type 2 diabetes Gevokizumab is a novel, human-engineered monoclonal anti–IL-1β antibody Study evaluated safety and biological activity of gevokizumab in patients with type 2 diabetes Cavelti-Weder C et al. Diabetes Care 2012;35:

Study Design 98 patients randomly assigned to placebo (17 subjects) or gevokizumab (81 subjects) at increasing doses and dosing schedules Primary objective of study was to evaluate the safety profile of gevokizumab Secondary objectives were to assess pharmacokinetics for different dose levels, routes of administration, and regimens and to assess biological activity Cavelti-Weder C et al. Diabetes Care 2012;35:

Results Study drug well tolerated with no serious adverse events One hypoglycemic event requiring reduction of dosage of concomitant insulin treatment Clearance of gevokizumab was consistent with that for human IgG 2, with a half-life of 22 days In the combined intermediate-dose group (single doses of 0.03 and 0.1 mg/kg), mean placebo-corrected decrease in A1C was 0.11, 0.44, and 0.85% after 1, 2 (P= 0.017), and 3 (P = 0.049) months, respectively Also observed enhanced C-peptide secretion, increased insulin sensitivity, and a reduction in C-reactive protein and spontaneous and inducible cytokines Cavelti-Weder C et al. Diabetes Care 2012;35:

Conclusions This novel IL-1β–neutralizing antibody improved glycemia, possibly via restored insulin production and action, and reduced inflammation in patients with type 2 diabetes This therapeutic agent may be able to be used on a once- every-month or longer schedule Cavelti-Weder C et al. Diabetes Care 2012;35: